查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1320023

非何傑金氏淋巴瘤治療市場：治療方法（化療、免疫療法、放射線治療）、細胞類型（B 細胞、T 細胞）分類 - 全球預測 2023-2030

Non-Hodgkin Lymphoma Treatment Market by Treatment (Chemotherapy, Immunotherapy, Radiation), Cell Type (B-cell, T-cell) - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球非何傑金氏淋巴瘤治療市場預計將顯著成長，預計到 2023 年將達到 82,0508 萬美元，年複合成長率為 7.89%，預計到 2030 年將達到驚人的 1398,713 萬美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球非何傑金氏淋巴瘤治療市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.非何傑金氏淋巴瘤治療的全球市場規模與預測為何？

2.在預測期內，COVID-19 對全球非何傑金氏淋巴瘤治療市場的阻礙因素與影響為何？

3.在預測期內，全球非何傑金氏淋巴瘤治療市場需要投資哪些產品/細分市場/應用/領域？

4.全球非何傑金氏淋巴瘤治療市場的競爭策略為何？

5. 全球非何傑金氏淋巴瘤治療市場的技術趨勢與法律規範是什麼？

6.全球非何傑金氏淋巴瘤治療市場主要供應商的市佔率是多少？

7. 哪些型態和策略性措施被認為適合進入全球非何傑金氏淋巴瘤治療市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 非何傑金氏淋巴瘤盛行率上升
      • 大量未滿足的臨床需求和有前景的藥物上市
      • NHL 患者預後和第一線治療計畫的照護標準
    • 抑制因素
      • 治療費用高且有一定的副作用
    • 機會
      • 加大疾病治療藥物的研發力度
      • 政府和非營利組織增加投資
    • 任務
      • 缺乏意識和資源有限
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 何杰金氏淋巴瘤治療市場（依治療）

  • 化學處理
  • 免疫療法
  • 輻射
  • 幹細胞移植
  • 標靶治療

第7章 何杰金氏淋巴瘤治療市場

  • B細胞
  • T細胞

第8章 美洲非何傑金氏淋巴瘤治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章 亞太非何傑金氏淋巴瘤治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲非何傑金氏淋巴瘤治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業

第12章上市公司名單

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-036C5CF3B519

The Global Non-Hodgkin Lymphoma Treatment Market is forecasted to grow significantly, with a projected USD 8,205.08 million in 2023 at a CAGR of 7.89% and expected to reach a staggering USD 13,987.13 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Non-Hodgkin Lymphoma Treatment Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Non-Hodgkin Lymphoma Treatment Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Treatment, market is studied across Chemotherapy, Immunotherapy, Radiation, Stem Cell Transplant, and Targeted Therapy. The Stem Cell Transplant is projected to witness significant market share during forecast period.

Based on Cell Type, market is studied across B-cell and T-cell. The B-cell is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Non-Hodgkin Lymphoma Treatment Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Non-Hodgkin Lymphoma Treatment Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Non-Hodgkin Lymphoma Treatment Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Non-Hodgkin Lymphoma Treatment Market?

4. What is the competitive strategic window for opportunities in the Global Non-Hodgkin Lymphoma Treatment Market?

5. What are the technology trends and regulatory frameworks in the Global Non-Hodgkin Lymphoma Treatment Market?

6. What is the market share of the leading vendors in the Global Non-Hodgkin Lymphoma Treatment Market?

7. What modes and strategic moves are considered suitable for entering the Global Non-Hodgkin Lymphoma Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Non-Hodgkin Lymphoma Treatment Market, by Treatment, 2022 vs 2030
  • 4.3. Non-Hodgkin Lymphoma Treatment Market, by Cell Type, 2022 vs 2030
  • 4.4. Non-Hodgkin Lymphoma Treatment Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of non-Hodgkin lymphoma disease
      • 5.1.1.2. High unmet clinical needs and the launch of promising drugs
      • 5.1.1.3. NHL patient prognosis and standard of care in front-line treatment regimens
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the treatment and certain side effects
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in research and development of therapeutic drugs against the disease
      • 5.1.3.2. Rising investments from government and non-profit organizations
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness and limited resources
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Non-Hodgkin Lymphoma Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Immunotherapy
  • 6.4. Radiation
  • 6.5. Stem Cell Transplant
  • 6.6. Targeted Therapy

7. Non-Hodgkin Lymphoma Treatment Market, by Cell Type

  • 7.1. Introduction
  • 7.2. B-cell
  • 7.3. T-cell

8. Americas Non-Hodgkin Lymphoma Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Non-Hodgkin Lymphoma Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2022 VS 2030
  • FIGURE 3. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
  • FIGURE 5. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2022 VS 2030 (%)
  • FIGURE 6. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. NON-HODGKIN LYMPHOMA TREATMENT MARKET DYNAMICS
  • FIGURE 8. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 5. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 100. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 101. NON-HODGKIN LYMPHOMA TREATMENT MARKET LICENSE & PRICING